Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Memory and Insulin in Early Alzheimer's Disease
Alzheimer's Disease
Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels
N/A N=15 Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Brain Glucose Consumption — 27.9; 28.1 umol/100 g/min
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 4 N=14 Neural Correlates In Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change
Phase 3 N=164 Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Mild Cognitive Impairment · Prodromal Alzheimer's Disease
Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 2 N=13 PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 2 N=64 PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087
Phase 4 N=12 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
Alzheimer Disease
Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…
Phase 2 N=71 Benfotiamine in Alzheimer's Disease: A Pilot Study
Alzheimer's Disease
Primary: Change From Baseline in ADAS-Cog Score — 1.39; 3.26 score on a scale — p=0.125
Phase 2 N=356 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Alzheimer Disease
Primary: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score — 1.02; 0.80; 1.07; 1.15 Score on a scale — p=0.7975
Phase 3 N=387 A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Alzheimer's Disease
Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants
Phase 2 N=36 Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
Alzheimer's Disease
Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale
N/A N=119 Exercise for Brain Health in the Fight Against Alzheimer's Disease
Healthy Cognition
Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5
N/A N=42 ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
Alzheimer Disease
Primary: Acute Safety — 2 participants
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
Phase 2 N=161 Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Alzheimer Disease
Primary: Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) — -0.09679; -0.15776 Z-score — p=0.564
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
N/A N=78 Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Alzheimer Disease · Dementia
Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items
Phase 3 N=1,169 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
Phase 1 N=11 Treatment of Language and Memory in Patients With Alzheimer's Disease
Alzheimer Disease
Primary: Number of Successful Memory Tasks Completed Over Study Period. — 5; 0 memory tasks
Phase 2 N=200 Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
Alzheimer's Disease · Dementia · Memory Loss
Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67
Phase 2 N=16 Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants
Phase 2 N=11 Endothelial Facilitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560